No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients

• Published in: Multiple sclerosis Vol. 18; no. 8; pp. 1188 - 1192
• Main Authors: Lutterotti, A, Jelčić, I, Schulze, C, Schippling, S, Breiden, P, Mazzanti, B, Reinhardt, S, DiGioia, M, Repice, A, Massacesi, L, Sputtek, A, Salinas-Riester, G, Kroeger, N, Sospedra, M, Saccardi, R, Zander, A, Martin, R
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.08.2012; Sage Publications; Sage Publications Ltd
• Subjects: Antigens, CD34 - analysis; Autografts; Biological and medical sciences; Case-Control Studies; CD34 antigen; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Donors; Female; Gene expression; Gene Expression Profiling - methods; Genomes; Genotype; Hematopoietic Stem Cells - immunology; Hemopoiesis; Humans; Immune system; Inflammation; Inflammation - genetics; Inflammation - immunology; Male; Medical sciences; MicroRNAs - analysis; miRNA; Multiple sclerosis; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Multiple Sclerosis, Chronic Progressive - genetics; Multiple Sclerosis, Chronic Progressive - immunology; Multiple Sclerosis, Relapsing-Remitting - genetics; Multiple Sclerosis, Relapsing-Remitting - immunology; Neurology; Peripheral blood; Phenotype; Principal Component Analysis; Statistics; stem cell transplantation; Stem cells; hematopoietic stem cell transplantation; multiple sclerosis; gene expression; Human; Nervous system diseases; Multiple sclerosis; Stem cell; Central nervous system disease; Degenerative disease; Transplantation; Gene expression; Inflammatory disease
• ISSN: 1352-4585; 1477-0970
• DOI: 10.1177/1352458511434067

Autologous hematopoietic stem cell transplantation (aHSCT) has been used as a therapeutic approach in multiple sclerosis (MS). However, it is still unclear if the immune system that emerges from autologous CD34+ hematopoietic progenitor cells (HPC) of MS patients is pre-conditioned to re-develop the proinflammatory phenotype. The objective of this article is to compare the whole genome gene and microRNA expression signature in CD34+ HPC of MS patients and healthy donors (HD). CD34+ HPC were isolated from peripheral blood of eight MS patients and five HD and analyzed by whole genome gene expression and microRNA expression microarray. Among the differentially expressed genes (DEGs) only TNNT1 reached statistical significance (logFC=3.1, p<0.01). The microRNA expression was not significantly different between MS patients and HD. We did not find significant alterations of gene expression or microRNA profiles in CD34+ HPCs of MS patients. Our results support the use of aHSCT for treatment of MS.